Rapid Resolution of Suicidal Ideation After a Single Infusion of an N -Methyl- D -Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Objective Suicidal ideation is a medical emergency, especially when severe. Little research has been done on pharmacologic interventions that could address this problem. Ketamine, an N-methyl-D-asparate antagonist, has been reported to have antidepressant effects within hours. We examined the effects of a single dose of ketamine on suicidal ideation in subjects with treatment-resistant major depressive disorder (MDD). Method Thirty-three subjects with DSM-IV-diagnosed MDD received a single open-label infusion of ketamine (0.5 mg/kg) and were rated at baseline and at 40, 80, 120, and 230 minutes postinfusion with the Scale for Suicide Ideation (SSI), the Montgomery-Åsberg Depression Rating Scale, the Hamilton Depression Rating Scale, and the Beck Depression Inventory. The study was conducted between October 2006 and January 2009. Results Suicidal ideation scores decreased significantly on the SSI as well as on the suicide subscales of other rating instruments within 40 minutes; these decreases remained significant through the first 4 hours postinfusion (P Conclusions Suicidal ideation in the context of MDD improved within 40 minutes of a ketamine infusion and remained improved for up to 4 hours postinfusion. Future studies with ketamine in suicidal ideation are warranted due to the potential impact on public health. Trial registration clinicaltrials.gov Identifier: NCT00088699.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The rapid-acting dissociative agent ketamine, which has shown its efficacy in treating depression, is known to increase BDNF levels (37, 38).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [38]
In the citing paper
“Extensive experience with human patients has established that ketamine exerts rapid, robust antidepressant, antianhedonic, and antisuicidal actions within two hours of administration that are sustained for at least seven days in patients with major depression following a single infusion or intranasal administration [129-133].”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [131]
In the citing paper
“Recent studies report that ketamine also reduces suicide ideation, a major advance over typical antidepressants with low efficacy and delayed onset of action151,152.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [151]
In the citing paper
“Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative anesthetic ketamine induces rapid and sustained antidepressant actions in treatment-resistant patients.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [7]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationAssessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419
Linehan, M. M., Comtois, K. A., Murray, A. M., Brown, M. Z., Gallop, R. J., Heard, H. L., Korslund, K. E., Tutek, D. A., Reynolds, S. K., & Lindenboim, N. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.757 · Cited by 2,025
Assessment of Depression: The Depression Inventory
Beck, A. T., & Beamesderfer, A. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000395074 · Cited by 1,832
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Cognitive Therapy for the Prevention of Suicide Attempts: A Randomized Controlled Trial
Brown, G. K., Ten Have, T., Henriques, G. R., Xie, S. X., Hollander, J. E., & Beck, A. T. (2005) · JAMA · doi:10.1001/jama.294.5.563 · Cited by 1,045
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Cited by
Items 301–400 of 570
Cohen, I. V., Makunts, T., Atayee, R. S., & Abagyan, R. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-01590-x · Cited by 29
Novel Targets for Fast Antidepressant Responses: Possible Role of Endogenous Neuromodulators
Camargo, A., & Rodrigues, A. L. S. (2019) · Chronic Stress · doi:10.1177/2470547019858083 · Cited by 28
Ren, Q., Ling, H., Zhou, X., Cheng, Y., Lu, M., Zhang, C., Guo, J., & Xu, H. X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.818822 · Cited by 30
“Within 24 h after treatment, more than 70% of the patients reached the standard response (with 50% improvement), and 35% remained effective after 1 week (Ibrahim et al., 2010).”
BackgroundAhmed, G. K., Elserogy, Y., Elfadl, G. M. A., Abdelsalam, K. G., & Ali, M. A. S. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.005 · Cited by 31
Moreira, D. D. A. S., Gauer, L. E., Teixeira, G., da Silva, A. C. F., Cavalcanti, S., & Quevedo, J. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.152 · Cited by 30
Effects of ketamine on major depressive disorder in a patient with posttraumatic stress disorder.
Womble, A. L. (2013) · PubMed · Cited by 27
Camargo, A., Dalmagro, A. P., Wolin, I. A. V., Kaster, M. P., & Rodrigues, A. L. S. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.09.057 · Cited by 26
The Effect of Intravenous Ketamine in Suicidal Ideation of Emergency Department Patients.
Kashani, P., Yousefian, S., Amini, A., Heidari, K., Younesian, S., & Hatamabadi, H. (2014) · Archives of Academic Emergency Medicine · doi:10.22037/aaem.v2i1.20 · Cited by 35
Matsumoto, R. R., Nguyen, L., Weaver, C., Cramér, K., Pollard, S., & Marshalek, P. J. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s88569 · Cited by 28
Fuxé, K., Borroto‐Escuela, D. O., Tarakanov, A. O., Romero‐Fernandez, W., Manger, P. R., Rivera, A., Craenenbroeck, K. V., Skieterska, K., Díaz-Cabiale, Z., Filip, M., et al. (2013) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2013.10.002 · Cited by 28
Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression
Hochschild, A., Keilp, J. G., Madden, S. P., Burke, A. K., Mann, J. J., & Grunebaum, M. F. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.055 · Cited by 25
Post-traumatic stress disorder: new directions in pharmacotherapy
Green, B. (2013) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.111.010041 · Cited by 27
Ketamine as a rapid antidepressant: the debate and implications
Ho, R. C. M., & Zhang, M. W. (2016) · BJPsych Advances · doi:10.1192/apt.bp.114.014274 · Cited by 24
Sex differences in brain gene expression among suicide completers
Cabrera‐Mendoza, B., Fresno, C., Monroy‐Jaramillo, N., Fries, G. R., Walss‐Bass, C., Glahn, D. C., Ostrosky‐Wegman, P., Mendoza-Morales, R., García‐Dolores, F., Díaz‐Otañez, C. E., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.167 · Cited by 26
NLRP3 inflammatory pathway. Can we unlock depression?
Jahromi, G. G., Razi, S., & Rezaei, N. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148644 · Cited by 26
Autism in the Son of a Woman with Mitochondrial Myopathy and Dysautonomia: A Case Report.
Lee, J., Narang, P., Enja, M., & Lippmann, S. (2015) · Europe PMC (PubMed Central) · Cited by 24
Ketamine and Lamotrigine Combination in Psychopharmacology: Systematic Review
Wilkowska, A., Wiglusz, M. S., Jakuszkowiak‐Wojten, K., & Cubała, W. J. (2022) · Cells · doi:10.3390/cells11040645 · Cited by 27
Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review
Benitah, K. C., Siegel, A. N., Lipsitz, O., Rodrigues, N. B., Meshkat, S., Lee, Y. L., Mansur, R. B., Nasri, F., Lui, L. M. W., McIntyre, R. S., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114579 · Cited by 25
Nikayin, S., & Sanacora, G. (2021) · CNS Drugs · doi:10.1007/s40263-021-00851-8 · Cited by 26
Brenna, C. T. A., Goldstein, B. I., Zarate, C. A., & Orser, B. A. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005037 · Cited by 24
Self-citationDifferential effects of NMDA receptor antagonism on spine density
Ruddy, R. M., Chen, Y., Milenkovic, M., & Ramsey, A. J. (2014) · Synapse · doi:10.1002/syn.21784 · Cited by 25
Pradhan, B., Kluewer-DAmico, J., Makani, R. D., & Parikh, T. (2015) · Journal of Trauma & Dissociation · doi:10.1080/15299732.2015.1046101 · Cited by 24
“5mg/kg body weight) in depression (DiazGranados et al., 2010) and in PTSD with co-morbid depression (Pradhan et al, 2013-15, unpublished data involving more than 1 year follow up of 15 adult patients with chronic PTSD) didn’t show any of these side effects.”
InfluentialPapp, M., Gruca, P., Łasoń, M., Litwa, E., Solecki, W., & Willner, P. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120967857 · Cited by 23
“The opportunity to develop such models was afforded by the clinical discovery of novel treatments that bring about rapid and sometimes lasting improvements in a high proportion of TRD patients, including the NMDA-receptor antagonist ketamine (Berman et al., 2000; DiazGranados et al., 2010; Zarate et al., 2006), and hi…”
BackgroundKetamine for Treatment-Resistant Mood Disorders
Park, L. T., Falodun, T. B., & Zarate, C. A. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180030 · Cited by 23
Self-citationColla, M., Offenhammer, B., Scheerer, H., Kronenberg, G., Vetter, S., Mutschler, J., Mikoteit, T., Bankwitz, A., Adank, A., Schaekel, L., et al. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.03.002 · Cited by 23
Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior
Mallick, F., & McCullumsmith, C. B. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0680-7 · Cited by 22
“Hopelessness has been independently and repeatedly associated with increased risk for suicidal ideation, suicide attempts, and death by suicide, both prospectively and retrospectively [1, 128, 138–147]. Ketamine has been shown to decrease 61 Page 6 of 14 Curr Psychiatry Rep (2016) 18: 61”
BackgroundInfluentialBhattaccharjee, S. A., Murnane, K. S., & Banga, A. K. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120007 · Cited by 23
Brain Gene Expression Pattern of Subjects with Completed Suicide and Comorbid Substance Use Disorder
Cabrera‐Mendoza, B., Monroy‐Jaramillo, N., Fries, G. R., Mendoza-Morales, R., García‐Dolores, F., Mendoza-Larios, A., Díaz‐Otañez, C. E., Walss‐Bass, C., Glahn, D. C., Ostrosky‐Wegman, P., et al. (2018) · Complex Psychiatry · doi:10.1159/000493940 · Cited by 24
Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders
Costi, S., Dam, N. T. V., & Murrough, J. W. (2015) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-015-0052-3 · Cited by 21
“[54], using the Beck Scale for Suicide Ideation (SSI) in a sample of TRD patients, reported that SI scores decreased significantly 40 min after ketamine infusion and remained significantly decreased 4 h post-infusion.”
BackgroundMethodKattimani, S., Sarkar, S., Menon, V., Muthuramalingam, A., & Nancy, P. (2016) · Journal of Neurosciences in Rural Practice · doi:10.4103/0976-3147.185505 · Cited by 24
“However, individual‐level interventions to abort suicide attempt from the time of emergence of suicidal ideas are crucial.[8,9] Knowledge of the average time of this Address for correspondence: Dr.”
BackgroundGallay, C. C., Forsyth, G., Can, A., Dutton, M., Jamieson, D., Jensen, E., Hermens, D. F., Bennett, M. R., & Lagopoulos, J. (2021) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2021.111369 · Cited by 22
Lewis, V., Rodrigue, B., Arsenault, E., Zhang, M., Taghavi‐Abkuh, F., Silva, W. C. C., Myers, M., Matta‐Camacho, E., & Aguilar‐Valles, A. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15652 · Cited by 21
Yoon, S. H., Song, W. S., Chung, G., Kim, S. J., & Kim, M. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01294-z · Cited by 22
“Notably, a single ketamine administration rapidly reduced suicidal thoughts in patients with depression 10,11 and behavioral despair in rodent models 12,13 .”
General Anesthetics to Treat Major Depressive Disorder: Clinical Relevance and Underlying Mechanisms
Vutskits, L. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002594 · Cited by 25
Predictors of Suicidal Ideation Among IBD Outpatients
Hashash, J. G., Vachon, A., Rivers, C. R., Regueiro, M. D., Binion, D. G., Altman, L., Williams, C., & Szigethy, E. (2018) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001094 · Cited by 22
Hales, C. A., Bartlett, J., Arban, R., Hengerer, B., & Robinson, E. S. J. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00797-3 · Cited by 20
Borroto‐Escuela, D. O., Pita-Rodríguez, M., Fores‐Pons, R., Barbancho, M. Á., Fuxé, K., & Narváez, M. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30092 · Cited by 25
“Presently, only electroconvulsive treatment and infusion of the N‐methyl‐D‐aspartate receptor antagonist ketamine (DiazGranados et al., 2010) are available for TRD treatment.”
BackgroundCui, Y., Yang, Y., Dong, Y., & Hu, H. (2018) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2018.83.036871 · Cited by 21
“1B), an inward rectifying potassiumchannel foundonastrocytes andmajorly responsible for setting their resting membrane potentials (RMPs) (Djukic et al. 2007; Olsen and Sontheimer 2008; Chever et al. 2010; Hibino et al. 2010; Sibille et al. 2015).”
BackgroundClinical overview of NMDA-R antagonists and clinical practice
Davoudian, P. A., & Wilkinson, S. T. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.04.004 · Cited by 21
Ketamine, benzoate, and sarcosine for treating depression
Cheng, Y., Lin, C., & Lane, H. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109351 · Cited by 21
Madjid, N., Lidell, V., Nordvall, G., Lindskog, M., Ögren, S.-O., Forsell, P., & Sandin, J. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06410-x · Cited by 19
Psychedelic Therapy: A Primer for Primary Care Clinicians—Ketamine
Evans, V. D., Arenas, A., Shinozuka, K., Tabaac, B. J., Beutler, B. D., Cherian, K. N., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001721 · Cited by 19
Yin, Y., Yan, J., Wei, Q., Sun, S., Ding, Y., Zhang, L., & Li, Y. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17324 · Cited by 20
“…a large body of evidence confirmed that a single low dose of ketamine elicits rapid (within several hours) and sustained (lasting about a week) antidepressant effects in clinical (DiazGranados et al., 2010; McCloud et al., 2015) and preclinical studies (Fullana et al., 2022; Rawat et al., 2022).”
Ketamine modulates TRH and TRH-like peptide turnover in brain and peripheral tissues of male rats
Pekary, A. E., Sattin, A., & Lloyd, R. L. (2015) · Peptides · doi:10.1016/j.peptides.2015.04.003 · Cited by 21
Fraga, D. B., Camargo, A., Olescowicz, G., Padilha, D. A., Mina, F., Budni, J., Brocardo, P. S., & Rodrigues, A. L. S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00743-2 · Cited by 22
Glutamine and New Pharmacological Targets to Treat Suicidal Ideation
Jiménez-Treviño, L., González-Blanco, L., Alvarez-Vázquez, C., Rodríguez-Revuelta, J., & Sáiz, P. A. (2020) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_168 · Cited by 20
Kadriu, B., Subramanian, S., Deng, Z., Henter, I. D., Park, L. T., & Zarate, C. A. (2019) · Oxford University Press eBooks · doi:10.1093/med/9780190929565.003.0013 · Cited by 18
Self-citationDahan, J. D. C., Dadiomov, D., Bostoen, T., & Dahan, A. (2024) · npj Mental Health Research · doi:10.1038/s44184-024-00091-w · Cited by 25
de Maricourt, P., Jay, T. M., GONCALVES, P. S., Löo, H., & Gaillard, R. (2014) · L Encéphale · doi:10.1016/j.encep.2013.09.001 · Cited by 18
Mania following ketamine abuse
Lane, H., Lu, Y., & Lin, C. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s97696 · Cited by 22
Ketamine Alters Electrophysiological Responses to Emotional Faces in Major Depressive Disorder
Lundin, N. B., Sepe-Forrest, L., Gilbert, J. R., Carver, F. W., Furey, M. L., Zarate, C. A., & Nugent, A. C. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.10.007 · Cited by 20
“…depression within 24 hours, with repeated administration producing a sustained response (Ballard et al., 2014; Berman et al., 2000; Diazgranados et al., 2010; Duman and Aghajanian, 2012; Fava et al., 2018; Murrough et al., 2013; Nugent et al., 2019a; Phillips et al., 2019; Zarate…”
BackgroundSelf-citationAntisuicidal efficacy of ketamine infusion in suicidal patients of depressive disorder
Pathak, U., Ahuja, S. K., Dwivedi, R., Mishra, N., Kumar, P. J., Mishra, D. K., & Singh, R. (2021) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_80_21 · Cited by 20
“[20] Subjects with MDD received a single infusion of ketamine (0.5 mg/kg) and rated at baseline, 40, 80, 120, and 230 min postinfusion with SSI, MADRS, and HAM-D17.”
InfluentialBest, S., & Griffin, B. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2014.933834 · Cited by 18
Lundin, N. B., Niciu, M. J., Luckenbaugh, D. A., Ionescu, D., Richards, E. M., Voort, J. V., Brutsché, N. E., Machado‐Vieira, R., & Zarate, C. A. (2014) · Pharmacopsychiatry · doi:10.1055/s-0034-1377042 · Cited by 18
“In MDD, decreased suicidal ideation has also been reported within 40 min and has persisted for up to 4 h [4].”
BackgroundSelf-citationBao, H., Ran, P., Zhu, M., Sun, L., Li, B., Hou, Y., Nie, J., Shan, L., Li, H., Zheng, S., et al. (2016) · Scientific Reports · doi:10.1038/srep28395 · Cited by 19
Kurzweil, L., Danyeli, L. V., Şen, Z. D., Fejtová, A., Walter, M., & Gensberger‐Reigl, S. (2020) · Journal of Chromatography B · doi:10.1016/j.jchromb.2020.122214 · Cited by 18
(Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy
Alario, A. A., & Niciu, M. J. (2022) · Chronic Stress · doi:10.1177/24705470221128017 · Cited by 18
“saline placebo in a cross-over, double-blind design.(16) By the end of the infusion, SSI, MADRS-SI, and the suicide items of the Beck Depression Index (BDI-SI) and Hamilton Depression Rating Scale (HDRS-SI) significantly improved.”
MethodPompili, M., Sarli, G., Erbuto, D., Manfredi, G., & Comparelli, A. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000455 · Cited by 19
Baranyi, A., Meinitzer, A., Rothenhäusler, H., Amouzadeh-Ghadikolai, O., von Lewinski, D., Breitenecker, R. J., & Herrmann, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208238 · Cited by 17
Marek, G. J., Day, M., & Hudzik, T. J. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229922 · Cited by 17
“effects and cognitive impairment that may be produced within the first 30–45minutes following ketamine administration, the clinical use of ketamine in depressed patients does appear to decrease suicidality (DiazGranados et al., 2010; Zarate et al., 2012; Ballard et al., 2014; Price et al., 2014).”
Ketamine for acute suicidality in the emergency department: A systematic review
Maguire, L. A., Bullard, T., & Papa, L. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.12.088 · Cited by 18
Martín-González, E., Prados-Pardo, Á., Mora, S., Flores, P., & Moreno, M. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4819-y · Cited by 17
“…has shown antidepressant efficacy (Ionescu et al. 2014; Phelps and Brutsche 2009; Sos et al. 2013; Zarate et al. 2006), decreased suicidal ideations (Diazgranados et al. 2010) and anhedonia (Lally et al. 2014), and reduced symptomatology in posttraumatic stress disorder (Feder et al. 2014).”
Chen, K. S., Dwivedi, Y., & Shelton, R. C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.07.054 · Cited by 17
Entactogen Effects of Ketamine: A Reverse-Translational Study
Hess, E. M., Greenstein, D. K., Hutchinson, O. L., Zarate, C. A., & Gould, T. D. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230980 · Cited by 17
Self-citationNovel uses of ketamine in the emergency department
Corwell, B. N., Motov, S. M., Davis, N. L., & Kim, H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2100883 · Cited by 16
“as an antidepressant therapy in patients with suicide ideation and depression [14,15].”
BackgroundWang, S., Tang, S., Huang, J., & Chen, H. (2022) · General Psychiatry · doi:10.1136/gpsych-2022-100922 · Cited by 15
Hasegawa, S., Yoshimi, A., Mouri, A., Uchida, Y., Hida, H., Mishina, M., Yamada, K., Ozaki, N., Nabeshima, T., & Noda, Y. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.12.020 · Cited by 18
Not So Fast: Recent Successes and Failures in Treating Depression
Kadriu, B., Deng, Z., Kraus, C., Henter, I. D., Lisanby, S. H., & Zarate, C. A. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19ac13138 · Cited by 16
Self-citationChaves, T. V., Wilffert, B., & Sanchez, Z. M. (2020) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1769118 · Cited by 16
Papp, M., Gruca, P., Łasoń, M., Litwa, E., Solecki, W., & Willner, P. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211048281 · Cited by 15
“After half a century in which there was very limited increase in the efficacy of antidepressant drugs, hope for treatment-resistant patients was kindled by the discovery of novel treatments that bring about rapid and sometimes lasting improvements in a high proportion of TRD patients, including the N-methyl-D-aspartat…”
BackgroundCriticisms of drugs in early development for the treatment of depression: what can be improved?
Wang, S., Han, C., & Pae, C. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.985784 · Cited by 17
“This effect was replicated and extended by other placebo-controlled studies illustrating ketamine’s rapid antidepressant effects in patients with TRD [45], depressed patients with suicidal ideation [46] and patients with treatment-resistant bipolar depression [47].”
ResultTucciarone, J., Bandeira, I. D., Blasey, C. M., Kratter, I. H., Ehrie, J., Keller, J., Pankow, H., Chang, M., Hawkins, J., Evers, A. G., et al. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250840 · Cited by 16
Nmda Receptor Antagonists for Depression: Critical Considerations
Serafini, G., Gonda, X., Rihmer, Z., Pompili, M., Girardi, P., Nasrallah, H. A., & Amore, M. (2015) · Annals of Clinical Psychiatry · doi:10.1177/104012371502700308 · Cited by 16
Buji, R. I., Murad, N. A. A., Chan, L. F., Maniam, T., Shahrir, M. S. M., Rozita, M., Shamsul, A. S., Hussain, R. M., Abdullah, N., Jamal, R., et al. (2017) · Lupus · doi:10.1177/0961203317742711 · Cited by 16
Hovda, N., Gerrish, W. G., Frizzell, W., & Shackelford, R. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.10.120 · Cited by 15
Psychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview
Tabaac, B. J., Shinozuka, K., Arenas, A., Beutler, B. D., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001727 · Cited by 15
Major challenges in youth psychopathology: treatment-resistant depression. A narrative review
Menculini, G., Cinesi, G., Scopetta, F., Cardelli, M., Caramanico, G., Balducci, P. M., Giorgi, F. D., Moretti, P., & Tortorella, A. A. V. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1417977 · Cited by 20
de Maricourt, P., Jay, T. M., GONCALVES, P. S., Löo, H., & Gaillard, R. (2014) · L Encéphale · doi:10.1016/j.encep.2013.09.002 · Cited by 15
Bozorgmehr, A., Alizadeh, F., Ofogh, S. N., Hamzekalayi, M. R. A., Herati, S., Moradkhani, A., Shahbazi, A., & Ghadirivasfi, M. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.12.079 · Cited by 15
High Yielding Continuous-Flow Synthesis of Norketamine
Veguillas, M., Moore, J. C., Howie, R. A., Castledine, R. A., Bourne, S. L., Jenkins, G. N., Licence, P., Poliakoff, M., & George, M. W. (2022) · Organic Process Research & Development · doi:10.1021/acs.oprd.1c00407 · Cited by 13
Matłoka, M., Janowska, S., Gajos‐Draus, A., Ziółkowski, H., Janicka, M., Perko, P., Kamil, K., Pankiewicz, P., Moszczyński-Pętkowski, R., Mach, M., et al. (2022) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2022.102127 · Cited by 14
Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions
McCartney, A., McGovern, H. T., & Foe, A. D. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00211 · Cited by 13
Papp, M., Gruca, P., Litwa, E., Łasoń, M., & Willner, P. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110715 · Cited by 13
Les antidépresseurs préviennent le suicide... en attendant mieux !
Courtet, P., & Olié, É. (2014) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)31294-4 · Cited by 17
Ketamine and Monoamine Oxidase Inhibitor Combination: Utility, Safety, Efficacy?
Bottemanne, H., Bonnard, E., Claret, A., Petit, A., Gaillard, R., & Fossati, P. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001281 · Cited by 12
Browne, C. A., Wulf, H. A., Jacobson, M. L., Oyola, M. G., Wu, T. J., & Lucki, I. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113963 · Cited by 13
Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions
Onisiforou, A., Georgiou, P., & Zanos, P. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173531 · Cited by 12
Rodgers, A., Bahceci, D., Davey, C. G., Chatterton, M. L., Glozier, N., Hopwood, M., & Loo, C. K. A. (2023) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674231203898 · Cited by 13
“However, replication and extension of initial trial findings was slow and haphazard; and only a few small, publicly funded trials were completed before 2015 (DiazGranados et al., 2010; Lai et al., 2014; Lapidus et al., 2014; Murrough et al., 2013; Zarate et al., 2006, 2010).”
BackgroundHassamal, S., Spivey, M., & Pandurangi, A. K. (2015) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000104 · Cited by 13
“Copyright © 2015 Wolters Kluwer H a target of treatment, ketamine has been associated with rapid antisuicidal effects as quickly as 40 minutes after a single infusion of IV ketamine.(23) To sustain the antidepressant effects of ketamine, studies have examined multiple IV ketamine infusions over a short duration of abo…”
BackgroundCurrent Trends in Identifying Rapidly Acting Treatments for Depression
Ionescu, D. F., & Papakostas, G. I. (2016) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-016-0075-4 · Cited by 13
Harraz, M. M., & Snyder, S. H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0540-0 · Cited by 12
“5 mg/kg of body weight, in several studies [6, 8, 9, 20].”
Botanas, C. J., Custodio, R. J. P., Kim, H. J., de la Peña, J. B., Sayson, L. V., Ortiz, D. M., Kim, M., Lee, H. J., Acharya, S., Kim, K., et al. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108619 · Cited by 14
Dong, Z., Grunebaum, M. F., Lan, M. J., Wagner, V., Choo, T.-H. J., Milak, M. S., Sobeih, T. M., Mann, J. J., & Kantrowitz, J. T. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.653026 · Cited by 13
Preventing Suicide among Psychiatric Inpatients with Psychotic Depression
Fredriksen, K. J., Schaufel, M. A., Johannessen, J. O., Walby, F. A., Davidson, L., & Schoeyen, H. K. (2019) · Psychiatric Quarterly · doi:10.1007/s11126-019-09677-6 · Cited by 17
“Although studies have suggested sleep problems as a modifiable risk factor and warning sign for suicidal behaviour [29, 30], acute pharmacological management as a suicide prevention strategy remains under-investigated [31].”
Jiang, Y., Dong, Y., & Hu, H. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0225 · Cited by 16
“Importantly, ketamine also reduced suicidal ideation in a rapid (within 40 min) and sustained (up to 1 week) manner [39,40].”
BackgroundO'Toole, E., Doucet, M. V., Sherwin, E., & Harkin, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802456-0.00003-0 · Cited by 12
Cabrera‐Mendoza, B., Martínez‐Magaña, J. J., Mendoza, A. D. G., Sarmiento, E., Ruíz-Ramos, D., Tovilla‐Zárate, C. A., González‐Castro, T. B., Juárez‐Rojop, I. E., la Cruz, D. D. G.-D., López‐Armenta, M., et al. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.01.008 · Cited by 12
Muscat, S.-A., Hartelius, G., Crouch, C., & Morin, K. W. (2022) · Psych · doi:10.3390/psych4010012 · Cited by 13
“For example, a study of 32 subjects with MDD treated with either a single ketamine dose of 0.44 mg/kg or remifentanil as active placebo (Sumner et al., 2021 [59]) found that dimensions of experience associated with insight, spirituality, and a sense of unity correlated with enhanced antidepressant response.”
BackgroundInfluentialWadhawan, A., Dagdag, A., Duffy, A., Daue, M., Ryan, K. A., Brenner, L. A., Stiller, J. W., Pollin, T. I., Groer, M. E., Huang, X., et al. (2017) · Pteridines · doi:10.1515/pterid-2017-0019 · Cited by 11
Clinical trials for rapid changes in suicidal ideation: lessons from ketamine
Ballard, E. D., Fields, J., Farmer, C. A., & Zarate, C. A. (2021) · Suicide and Life-Threatening Behavior · doi:10.1111/sltb.12663 · Cited by 10
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript subjects with more severe forms of SI (DiazGranados et al., 2010a; Price et al., 2009, 2014).”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A.
- Affiliations
- National Institute of Mental Health (US)
- National Institutes of Health (US)
- Corresponding author
- Zarate, Carlos A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-07-13
- Volume
- 71
- Issue
- 12
- Pages
- 1605-1611
- ISSN
- 0160-6689 (ISSN-L)
- PMC
- PMC3012738
- OpenAlex
- W2103255996
- Cited by
- 564
- References
- 41
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 22 · 2023: 21 · 2022: 41 · 2021: 41 · 2020: 39 · 2019: 35 · 2018: 49 · 2017: 33 · 2016: 51 · 2015: 59 · 2014: 52 · 2013: 40 · 2012: 30
- FWCI
- 23.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (Z99 MH999999)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- suicidal ideation, ketamine, NMDA receptor antagonists, rapid antidepressant effects, single-dose infusion, hopelessness, anxiety, depression
- MeSH terms
- Adult, Antidepressive Agents, Depression, Depressive Disorder, Major, Major Depressive Disorder, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Psychiatric Status Rating Scales, Time Factors, N-Methylaspartate, Treatment Outcome, Excitatory Amino Acid Antagonists, Diagnostic and Statistical Manual of Mental Disorders, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.